{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:38:13Z","timestamp":1790865493722,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Program of Tongzhou District Science & Technology Commission","award":["JCQN2023015"],"award-info":[{"award-number":["JCQN2023015"]}]},{"name":"Beijing Municipal Health Commission High Level Public Health Talent Construction Project","award":["Discipline Leader 03-11"],"award-info":[{"award-number":["Discipline Leader 03-11"]}]},{"name":"Beijing Hospital Management Center \"Dengfeng\" Talent Training Program","award":["DFL20221401"],"award-info":[{"award-number":["DFL20221401"]}]},{"name":"Program of Beijing Research Ward Excellence Program, BRWEP","award":["BRWEP2024W042160101"],"award-info":[{"award-number":["BRWEP2024W042160101"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z221100007422064"],"award-info":[{"award-number":["Z221100007422064"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Delamanid (DLM) is a promising drug recommended for treatment of multidrug-\/rifampicin-resistant tuberculosis (MDR\/RR-TB). However, there are very little data about the emergence of drug resistance in patients with the use of DLM-containing regimens. The study aimed to monitor the dynamics of susceptibility of MTB to DLM and investigate the potential mechanism conferring decreased susceptibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective cohort study was conducted, enrolling MDR\/RR-TB patients with culture-confirmed diagnoses across 10 study sites. Serial sputum samples were collected from participants receiving DLM-containing regimens at baseline (treatment initiation), week 2, week 4, and every 4 weeks thereafter until treatment completion. The in vitro susceptibility of\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      isolates to DLM was assessed using the BACTEC MGIT 960 system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 263 MDR\/RR-TB patients were included from 2020 to 2024 in the present study, favorable outcomes were recorded in 187 patients (71.1%). The distribution of minimal inhibit concentration (MIC) for a bacterial population to DLM was unimodal, and most isolates tested had a MIC value of &lt;\u20090.015\u00a0\u00b5g\/mL. The MIC\n                      <jats:sub>50<\/jats:sub>\n                      and MIC\n                      <jats:sub>90<\/jats:sub>\n                      of MTB isolates were 0.03 and 0.06\u00a0\u00b5g\/mL, respectively. Using the 0.12\u00a0\u00b5g\/mL as a proposed epidemiological cutoff value, the resistance to DLM was found in 0.76% (2\/263) of MTB isolates and no mutations were identified within loci conferring DLM resistance. Additionally, the remaining 81 (30.8%) with serial isolates were included in our analysis. 70 out of 81 patients exhibited no change in DLM MICs. In contrast, the reduced susceptibility to DLM was noted in 11 patients, defined as no less than 2-fold increase in MIC value compared with that of baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Primary DLM resistance was rare (0.76%), and resistance emergence during treatment was infrequent, though some cases of reduced susceptibility were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12941-025-00820-9","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:32:45Z","timestamp":1782973965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rare emergence of delamanid resistance in multidrug-\/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Wei","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"820_CR1","doi-asserted-by":"publisher","DOI":"10.54394\/CJQU6666","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024."},{"issue":"9","key":"820_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S2213-2600(19)30263-2","volume":"7","author":"K Dheda","year":"2019","unstructured":"Dheda K, Gumbo T, MaartenS G, et al. The lancet respiratory medicine commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9):820\u20136.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"820_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"TacconellI E, Carrara E. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"820_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/phar.1868","volume":"37","author":"H Luepke K H, Suda K J, BoucheR","year":"2017","unstructured":"Luepke K H, Suda K J, Boucher H, et al. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy. 2017;37(1):71\u201384.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"820_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","volume":"74","author":"JH RYAN N J, LO","year":"2014","unstructured":"Ryan N J, Lo JH. Delamanid: first global approval. Drugs. 2014;74(9):1041\u20135.","journal-title":"Drugs"},{"issue":"10362","key":"820_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"J Mok","year":"2022","unstructured":"Mok J, Lee M, Kim D K, et al. 9 months of delamanid, linezolid, levofloxacin, and Pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522\u201330.","journal-title":"Lancet"},{"issue":"3","key":"820_CR7","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/cid\/ciac528","volume":"76","author":"C Padmapriyadarsini","year":"2022","unstructured":"Padmapriyadarsini C, Vohra V. Bedaquiline, delamanid, linezolid and Clofazimine for treatment of Pre-extensively Drug-Resistant tuberculosis. Clin Infect Dis. 2022;76(3):e938\u201346.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"820_CR8","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"M T Gler","year":"2012","unstructured":"Gler M T, Sanchez-garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151\u201360.","journal-title":"N Engl J Med"},{"issue":"Suppl 1Suppl 1","key":"820_CR9","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","volume":"124","author":"MJ Nasiri","year":"2022","unstructured":"Nasiri MJ, Zangiabadian M. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Int J Infect Dis. 2022;124(Suppl 1Suppl 1):S90\u2013103.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"820_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cmi.2020.06.004","volume":"27","author":"M Gao","year":"2021","unstructured":"Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in china: a multicentre study. Clin Microbiol Infect. 2021;27(4):597\u2013602.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"820_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.46234\/ccdcw2021.053","volume":"3","author":"RUBINEJ Guinn K M","year":"2021","unstructured":"Guinn K M RUBINEJ. Implementing new approaches to tuberculosis control. China CDC Wkly. 2021;3(12):256\u20139.","journal-title":"China CDC Wkly"},{"issue":"20","key":"820_CR12","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMc1505196","volume":"373","author":"D Bloemberg G V, KELLER P M, STUCKI","year":"2015","unstructured":"Bloemberg G V, Keller P M, StuckI D, et al. Acquired resistance to bedaquiline and Delamanid in therapy for tuberculosis. N Engl J Med. 2015;373(20):1986\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"820_CR13","doi-asserted-by":"publisher","first-page":"e0053122","DOI":"10.1128\/aac.00531-22","volume":"66","author":"Y Liu","year":"2022","unstructured":"Liu Y, Shi J, LI L, et al. Spontaneous mutational patterns and novel mutations for Delamanid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2022;66(12):e0053122.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"820_CR14","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1093\/cid\/ciaa755","volume":"71","author":"Nguyen T V A","year":"2020","unstructured":"Nguyen T V A, Anthony R M, Cao T T H, et al. Delamanid resistance: update and clinical management. Clin Infect Dis. 2020;71(12):3252\u20139.","journal-title":"Clin Infect Dis"},{"key":"820_CR15","volume-title":"Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization; 2018."},{"issue":"1","key":"820_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12941-022-00537-z","volume":"21","author":"W Wang","year":"2022","unstructured":"Wang W, Li S, Ge Q, et al. Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thya, FolC and DfrA mutations. Ann Clin Microbiol Antimicrob. 2022;21(1):48.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"820_CR17","unstructured":"Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria,nocardiae, and other aerobic actinomycetes; approved standard. 2nd ed.Wayne, PA: Clinical and Laboratory Standards Institute. 2011:M24\u2013A2."},{"issue":"4","key":"820_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","volume":"22","author":"H Ismail N A, Omar S V, Moultrie","year":"2022","unstructured":"Ismail N A, Omar S V, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022;22(4):496\u2013506.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"820_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","volume":"7","author":"R VON Groote-Bidlingmaier F, PATIENTI","year":"2019","unstructured":"VON Groote-Bidlingmaier F, PATIENTIA R. Efficacy and safety of Delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249\u201359.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"820_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3343\/alm.2018.38.6.563","volume":"38","author":"JS YANG","year":"2018","unstructured":"Yang JS, Kim K J, Choi H, et al. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and Resistance-related gene mutations in Multidrug-resistant and extensively Drug-resistant tuberculosis in Korea. Ann Lab Med. 2018;38(6):563\u20138.","journal-title":"Ann Lab Med"},{"issue":"7","key":"820_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10096-019-03551-w","volume":"38","author":"S Wen","year":"2019","unstructured":"Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles Delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2019;38(7):1293\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"820_CR22","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1128\/AAC.06460-11","volume":"56","author":"L Fenner","year":"2012","unstructured":"Fenner L, Egger M, Bodmer T, et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(6):3047\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"820_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mimet.2017.06.007","volume":"139","author":"P Gallo J F, Pinhata J M W, Saraceni","year":"2017","unstructured":"Gallo J F, Pinhata J M W, Saraceni C P, et al. Evaluation of the BACTEC MGIT 960 system and the resazurin microtiter assay for susceptibility testing of Mycobacterium tuberculosis to second-line drugs. J Microbiol Methods. 2017;139:168\u201371.","journal-title":"J Microbiol Methods"},{"issue":"11","key":"820_CR24","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.1128\/AAC.01117-15","volume":"59","author":"S Heysell S K, Pholwat","year":"2015","unstructured":"Heysell S K, Pholwat S, Mpagama S G, et al. Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in tanzania: a call to operationalize mics. Antimicrob Agents Chemother. 2015;59(11):7104\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"820_CR25","doi-asserted-by":"publisher","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","volume":"73","author":"Y Liu","year":"2021","unstructured":"Liu Y, Gao M, Du J, et al. Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. Clin Infect Dis. 2021;73(9):e3391\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"820_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/jac\/dkh377","volume":"54","author":"S Bonora","year":"2004","unstructured":"di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother. 2004;54(3):593\u2013602.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"820_CR27","doi-asserted-by":"publisher","first-page":"e0009023","DOI":"10.1128\/spectrum.00090-23","volume":"11","author":"J Shi","year":"2023","unstructured":"Shi J, Liu Y, Wu T, et al. Spontaneous mutational patterns and novel mutations for bedaquiline and Clofazimine resistance in Mycobacterium tuberculosis. Microbiol Spectr. 2023;11(5):e0009023.","journal-title":"Microbiol Spectr"},{"issue":"3","key":"820_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jac\/dkp237","volume":"64","author":"R BergvaL I L, Schuitema A R, Klatser","year":"2009","unstructured":"Bergval I L, Schuitema A R, Klatser P R, et al. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of Isoniazid resistance. J Antimicrob Chemother. 2009;64(3):515\u201323.","journal-title":"J Antimicrob Chemother"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-025-00820-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:32:54Z","timestamp":1782973974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12941-025-00820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["820"],"URL":"https:\/\/doi.org\/10.1186\/s12941-025-00820-9","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Beijing Chest Hospital, Capital Medical University \u201c(2020) Clinical review NO.09\u201d. All the relevant patients had signed an informed consent form to take part in our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}